Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells $15,544.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 536 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00. Following the completion of the sale, the chief operating officer directly owned 181,641 shares in the company, valued at approximately $5,267,589. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00.

Bicara Therapeutics Stock Performance

BCAX stock traded down $0.77 on Friday, reaching $28.91. The company had a trading volume of 584,437 shares, compared to its average volume of 609,333. The company’s fifty day moving average is $23.27 and its 200 day moving average is $20.04. The company has a market cap of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81. Bicara Therapeutics Inc. has a 1 year low of $9.47 and a 1 year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, sell-side analysts predict that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Citizens Jmp reissued a “market outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Morgan Stanley upped their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Guggenheim assumed coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.27.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth $1,579,000. UBS Group AG boosted its holdings in Bicara Therapeutics by 97.4% in the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after acquiring an additional 94,829 shares during the last quarter. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics during the third quarter valued at about $661,000. Walleye Capital LLC purchased a new stake in Bicara Therapeutics during the first quarter valued at about $2,148,000. Finally, Candriam S.C.A. acquired a new stake in Bicara Therapeutics during the first quarter worth about $4,750,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.